Observational studyWorld journal of gastroenterology2017
Antimicrobial susceptibility testing before first-line treatment for
Observational study in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Review
- Article
- Incorporation ofFoods (Basel, Switzerland) · 2022Article
- Empirical vs. Susceptibility-Guided Treatment ofFrontiers in microbiology · 2022Article
- Emphasizing the importance of successful eradication ofAmerican journal of cancer research · 2022Review
- Antibiotic Resistance Prevalence and Trends in Patients Infected withAntibiotics (Basel, Switzerland) · 2021Article
- Rifabutin for the Treatment ofPathogens (Basel, Switzerland) · 2020Review
- Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.Journal of gastroenterology · 2020Article
- BestAntibiotics (Basel, Switzerland) · 2020Review
- Reevaluation of the Efficacy of First Line Regimen forClinical and experimental gastroenterology · 2020Article
- Development ofWorld journal of gastroenterology · 2019Review
- Rifabutin-Based Rescue Therapy forJournal of clinical medicine · 2019Article
- Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.Annals of clinical microbiology and antimicrobials · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy of antimicrobial susceptibility-guided therapy before first-line treatment for infection in patients with dual or triple antibiotic resistance.
methodsA total of 1034 patients infected by
resultsIntention-to-treat eradication rates were: OAL (97.6%), OAM (91.6%), OAC (92.3%) and OAR (58.3%). Cure rate was significantly higher in naïve patients treated with OAR-10 compared to patients who had two or three previous treatment failures (83%
conclusionAntimicrobial susceptibility-guided triple therapies during 10 d for first-line treatment leads to an eradication rate superior to 90% in patients with dual antibiotic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.